Rajan K Tripathy
Overview
Explore the profile of Rajan K Tripathy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tripathy R, Pande A
Pharm Res
. 2025 Feb;
42(2):219-236.
PMID: 39953265
As of now, more than 15 oligonucleotide drugs, primarily small interfering RNAs and antisense oligonucleotide classes, have been approved by the US FDA for therapeutic use, and many more are...
2.
Ahmed S, Tripathy R, Pande A, Sharma S
Int J Biol Macromol
. 2025 Feb;
304(Pt 2):140790.
PMID: 39924027
Stroke is the second leading cause of death worldwide, and currently, there is no effective neuroprotective agent available for its treatment. Though apolipoprotein E (ApoE) showed potential as a neuroprotective...
3.
Tripathy R, Khandave P, Bzdrenga J, Nachon F, Brazzolotto X, Pande A
Arch Toxicol
. 2024 Oct;
99(2):447-465.
PMID: 39356346
Chemical warfare nerve agents (CWNA) are neurotoxic chemicals unethically used as agents of mass destruction by terrorist outfits and during war. The available antidote against CWNA-mediated toxicity is not sufficiently...
4.
Tripathy R, Pande A
Life Sci
. 2024 Mar;
345:122593.
PMID: 38554946
Targeted therapy and imaging are the most popular techniques for the intervention and diagnosis of cancer. A potential therapeutic target for the treatment of cancer is the epidermal growth factor...
5.
Tripathy R, Anakha J, Pande A
Biochim Biophys Acta Gen Subj
. 2023 Nov;
1868(1):130499.
PMID: 37914146
Background: L-asparaginase (ASNase) has played a key role in the management of acute lymphoblastic leukaemia (ALL). As an amidohydrolase, it catalyzes the hydrolysis of L-asparagine, a crucial step in the...
6.
Pal D, Tripathy R, Teja M, Kumar M, Banerjee U, Pande A
3 Biotech
. 2018 Jan;
8(1):36.
PMID: 29291149
Recombinant human interferon-β (rhIFN-β), a therapeutic protein, is produced using both prokaryotic and eukaryotic expression systems. However, instability of recombinant plasmid during cultivation of results in low yield of the...
7.
Tripathy R, Aggarwal G, Bajaj P, Kathuria D, Bharatam P, Pande A
Appl Biochem Biotechnol
. 2017 Feb;
182(4):1642-1662.
PMID: 28161867
Human paraoxonase 1 (h-PON1) is a ~45-kDa serum enzyme that can hydrolyze a variety of substrates, including organophosphate (OP) compounds. It is a potential candidate for the development of antidote...
8.
Bajaj P, Tripathy R, Aggarwal G, Datusalia A, Sharma S, Pande A
Appl Biochem Biotechnol
. 2016 May;
180(1):165-76.
PMID: 27131877
Organophosphate (OP) compounds are neurotoxic chemicals, and current treatments available for OP-poisoning are considered as unsatisfactory and inadequate. There is an urgent need for the development of more effective treatment(s)...
9.
Aggarwal G, Prajapati R, Tripathy R, Bajaj P, Iyengar A, Sangamwar A, et al.
PLoS One
. 2016 Feb;
11(2):e0147999.
PMID: 26829396
Human paraoxonase 1 (h-PON1) is a serum enzyme that can hydrolyze a variety of substrates. The enzyme exhibits anti-inflammatory, anti-oxidative, anti-atherogenic, anti-diabetic, anti-microbial and organophosphate-hydrolyzing activities. Thus, h-PON1 is a...
10.
Parikh H, Bajaj P, Tripathy R, Pande A
Protein Pept Lett
. 2015 Oct;
22(12):1098-103.
PMID: 26428299
SsoPox, a ~35 kDa enzyme from Sulfolobus solfataricus, can hydrolyze and inactivate a variety of organophosphate (OP)-compounds. The enzyme is a potential candidate for the development of prophylactic and therapeutic...